Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest tauopathy Stories

2014-04-22 12:09:23

Research published in the Journal of Molecular Biology Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases. These molecules are based on what the Company calls a general amyloid interaction motif, or GAIM, which recognizes a characteristic common to many toxic, misfolded proteins, not just...

2014-04-14 14:20:45

Alzheimer's disease, the primary cause of dementia in the elderly, imposes a tremendous social and economic burden on modern society. In Japan, the burden of the disease in 2050 is estimated to be a half a trillion US dollars, a figure equivalent to the government's annual revenues. Unfortunately, it has proven very difficult to develop drugs capable of ameliorating the disease. After a tremendous burst of progress in the 1990s, the pace of discoveries has slowed. Dr. Saido believes that...

2014-01-16 23:27:40

Study indicates potential for TauC3 to be disease-modifying. Englewood Cliffs, New Jersey (PRWEB) January 16, 2014 Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic and diagnostic agents for the treatment of Alzheimer's and other neurological diseases, today announced it obtained proof of concept in a preclinical Alzheimer's model for its TauC3 monoclonal antibody indicating its...

2014-01-06 04:21:53

Clinical research centers added to allow more patients to access a tau-based investigational treatment for mild to moderate Alzheimer's disease ABERDEEN, Scotland, Jan. 6, 2014 /PRNewswire/ -- TauRx Therapeutics Ltd, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer's disease, has expanded its international clinical trials by adding new research centers across the U.S. The addition of 35 clinical research centers means that more patients suffering...

Alzheimer's Development And Progression Seen Through New Imaging Agents
2013-09-20 04:27:08

redOrbit Staff & Wire Reports - Your Universe Online Researchers have created a new class of imaging agents that could allow them to view the biological processes that occur in the brain during the development and progression of Alzheimer’s disease, according to research appearing in Wednesday’s edition of the journal Neuron. Senior author Dr. Makoto Higuchi of the National Institute of Radiological Sciences in Japan and colleagues have developed a fluorescent compound that...

2013-09-19 16:25:37

Over 300 patients now enrolled worldwide in clinical trials for a second-generation tau aggregation inhibitor (TAI) aimed at halting the progression of Alzheimer's SINGAPORE and ABERDEEN, Scotland, Sept. 19, 2013 /PRNewswire/ -- In advance of World Alzheimer's Day, TauRx Therapeutics Ltd announced that it has reached an important milestone with over 300 patients now enrolled in its global Phase 3 clinical trials of LMTX(TM) for mild to moderate Alzheimer's disease. More than 100...

2013-09-10 12:29:19

Research Focused on Development of Small Molecule Drugs Inhibiting Tau Aggregation NEW YORK, Sept. 10, 2013 /PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today the receipt of a two-year Small Business Innovation Research (SBIR) Phase IIB grant for $1.7M from the National Institutes of Health (NIH), National Institute on Aging (NIA)....

2013-09-04 16:27:51

100,000 Strong; Caregivers, family members and patients with mild dementia give Alzheimer's Team the thumbs up, marking a great start to Alzheimer's Awareness Month! KING OF PRUSSIA, Pa., Sept. 4, 2013 /PRNewswire/ -- Alzheimer's Team, the online Facebook community dedicated to advancing new Alzheimer's treatments through clinical trials reached 100,000 Facebook 'Likes' this week, marking a great start to Alzheimer's Awareness month in the US. Alzheimer's Team Facebook page...

Research Points To Potential Therapeutic Approach To Alzheimer's Disease
2013-06-26 15:32:27

University of California - Santa Barbara Building on research published eight years ago in the journal Chemistry and Biology, Kenneth S. Kosik, Harriman Professor in Neuroscience and co-director of the Neuroscience Research Institute (NRI) at UC Santa Barbara, and his team have now applied their findings to two distinct, well-known mouse models, demonstrating a new potential target in the fight against Alzheimer's and other neurodegenerative diseases. The results were published online...

2013-04-17 08:29:34

Investment is an Important Advancement in the Company's Long-term Commitment to Bringing New Medicines to Millions of Alzheimer's Disease Patients Who Are Waiting INDIANAPOLIS, April 17, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it has acquired two investigational positron emission tomography (PET) tracers from Siemens Medical Solutions USA, Inc. The tracers are intended to image tau (or neurofibrillary) tangles in the brain, one of two known hallmarks...